⚕️ Medical Disclaimer
⚕️ Medical Disclaimer: Educational overview of senolytic and klotho research themes. Not a protocol. Not a recommendation to use experimental peptides or gene therapies.
What This Essay Covers — And What We Do Not Have
CalcMyPeptide does not currently maintain a dedicated klotho peptide leaf. If you landed here looking for “klotho peptide dosage,” stop: we will not invent a page that does not exist. Klotho is primarily discussed in biology as an aging-related protein/hormone axis (α-klotho), not as a catalog research peptide on this site.
What we do have: an experimental senolytic peptide leaf for FOXO4-DRI and a related essay stub history under foxo4-dri-senolytic-peptide. This page is the honest overview that links those assets without pretending FOXO4-DRI equals “senolytics done” or that klotho is a vial in our library.
Senolytics in Plain Language
Senescence is a durable cell state: damaged cells stop dividing but linger and secrete inflammatory signals (the senescence-associated secretory phenotype, SASP). Senolytic strategies aim to clear senescent cells; senomorphic strategies aim to quiet the SASP without killing the cell.
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt FOXO4–p53 binding in senescent cells, freeing p53 to drive apoptosis in those cells in preclinical models. The landmark mouse work is Baar et al., Cell 2017 (PMID 28340339). That is mouse proof-of-concept — not a human frailty drug and not a reason to scale mg/kg mouse doses onto a person.
Human clinical programs for non-peptide senolytics (for example dasatinib + quercetin combinations in research settings) are a separate evidence body. This site will not merge them into a FOXO4-DRI shopping list.
Klotho — Mechanism Literacy Without a Fake Leaf
α-Klotho appears in aging biology as a protein linked to phosphate metabolism, FGF23 signaling, and broader “longevity factor” hypotheses. Soluble klotho levels and genetic variants show up in observational and preclinical literature. That is not the same as a gray-market “klotho peptide” SKU with a reconstitution chart.
Until we open a primary clinical program that justifies a compound leaf under our identity rules, klotho stays in the essay lane: mechanism literacy, not a catalog dose card. Do not treat forum vials labeled “klotho” as authenticated biologics.
How to Use This Site’s Longevity Tools Without Magical Thinking
• Experimental senolytic peptide identity: FOXO4-DRI.
• Mitochondrial / mitophagy oral ingredient: urolithin A and its essay.
• NAD+ precursor identity: NMN and NMN vs NR vs NAD.
• Telomere / bioregulator folklore: Epitalon leaves and Khavinson guides — different tradition, different evidence limits.
Stacking senolytics with everything else in a “longevity protocol” is community practice. We opened no combination RCT that blesses FOXO4-DRI + klotho folklore + NMN as a single regimen. Label stacks as anecdote.